USD 0.07
(14.55%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | - USD | -100.0% |
2022 | 411 Thousand USD | 77.92% |
2021 | 231 Thousand USD | 139.13% |
2020 | 96.6 Thousand USD | 0.0% |
2019 | - USD | 0.0% |
2018 | - USD | 0.0% |
2017 | - USD | 0.0% |
2016 | - USD | 0.0% |
2015 | - USD | 0.0% |
2014 | - USD | -100.0% |
2013 | 68.42 Thousand USD | 0.0% |
2012 | - USD | -100.0% |
2011 | 666.66 Thousand USD | -80.9% |
2010 | 3.48 Million USD | -21.37% |
2009 | 4.43 Million USD | -14.92% |
2008 | 5.21 Million USD | -11.59% |
2007 | 5.9 Million USD | 46.97% |
2006 | 4.01 Million USD | -11.17% |
2005 | 4.51 Million USD | 0.63% |
2004 | 4.49 Million USD | 20.4% |
2003 | 3.73 Million USD | -4.48% |
2002 | 3.9 Million USD | -6.06% |
2001 | 4.15 Million USD | -5.94% |
2000 | 4.41 Million USD | -1.39% |
1999 | 4.48 Million USD | 6.71% |
1998 | 4.2 Million USD | 1300.0% |
1997 | 300 Thousand USD | 50.0% |
1996 | 200 Thousand USD | 122.22% |
1995 | 90 Thousand USD | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q2 | - USD | 0.0% |
2024 Q1 | - USD | 0.0% |
2023 Q2 | - USD | 0.0% |
2023 Q3 | - USD | 0.0% |
2023 Q4 | - USD | 0.0% |
2023 FY | - USD | -100.0% |
2023 Q1 | - USD | -100.0% |
2022 Q4 | 411 Thousand USD | 0.0% |
2022 Q3 | 411 Thousand USD | 24.17% |
2022 Q2 | 331 Thousand USD | 17.79% |
2022 FY | 411 Thousand USD | 77.92% |
2022 Q1 | 281 Thousand USD | 21.65% |
2021 FY | 231 Thousand USD | 139.13% |
2021 Q3 | 231 Thousand USD | 0.0% |
2021 Q4 | 231 Thousand USD | 0.0% |
2021 Q1 | 156 Thousand USD | 61.49% |
2021 Q2 | 231 Thousand USD | 48.08% |
2020 Q4 | 96.6 Thousand USD | 132.21% |
2020 Q3 | 41.6 Thousand USD | 0.0% |
2020 Q2 | 41.6 Thousand USD | 0.0% |
2020 Q1 | - USD | 0.0% |
2020 FY | 96.6 Thousand USD | 0.0% |
2019 Q2 | - USD | 0.0% |
2019 FY | - USD | 0.0% |
2019 Q4 | - USD | 0.0% |
2019 Q3 | - USD | 0.0% |
2019 Q1 | - USD | 0.0% |
2018 Q3 | - USD | 0.0% |
2018 Q1 | - USD | 0.0% |
2018 FY | - USD | 0.0% |
2018 Q4 | - USD | 0.0% |
2018 Q2 | - USD | 0.0% |
2017 Q3 | - USD | 0.0% |
2017 Q2 | - USD | 0.0% |
2017 Q1 | - USD | 0.0% |
2017 FY | - USD | 0.0% |
2017 Q4 | - USD | 0.0% |
2016 Q1 | - USD | 100.0% |
2016 Q2 | - USD | 0.0% |
2016 Q3 | - USD | 0.0% |
2016 Q4 | - USD | 0.0% |
2016 FY | - USD | 0.0% |
2015 Q2 | - USD | 0.0% |
2015 Q3 | - USD | 0.0% |
2015 FY | - USD | 0.0% |
2015 Q1 | - USD | 0.0% |
2015 Q4 | -105.17 Thousand USD | 0.0% |
2014 Q4 | - USD | -100.0% |
2014 FY | - USD | -100.0% |
2014 Q3 | 41.92 Thousand USD | -59.07% |
2014 Q2 | 102.42 Thousand USD | 31.81% |
2014 Q1 | 77.7 Thousand USD | 13.55% |
2013 Q1 | - USD | 0.0% |
2013 FY | 68.42 Thousand USD | 0.0% |
2013 Q4 | 68.42 Thousand USD | 0.0% |
2013 Q3 | 68.42 Thousand USD | -1.21% |
2013 Q2 | 69.26 Thousand USD | 0.0% |
2012 Q1 | 1.15 Million USD | 72.94% |
2012 Q2 | 687.5 Thousand USD | -40.37% |
2012 Q3 | 409.41 Thousand USD | -40.45% |
2012 Q4 | - USD | -100.0% |
2012 FY | - USD | -100.0% |
2011 Q4 | 666.66 Thousand USD | -80.65% |
2011 Q3 | 3.44 Million USD | -1.38% |
2011 FY | 666.66 Thousand USD | -80.9% |
2011 Q2 | 3.49 Million USD | 551.67% |
2011 Q1 | 536.1 Thousand USD | -84.64% |
2010 Q2 | 3.83 Million USD | -1.79% |
2010 Q4 | 3.48 Million USD | -7.18% |
2010 Q3 | 3.75 Million USD | -1.94% |
2010 Q1 | 3.9 Million USD | -12.04% |
2010 FY | 3.48 Million USD | -21.37% |
2009 Q2 | 5.08 Million USD | -7.86% |
2009 Q1 | 5.51 Million USD | 5.78% |
2009 FY | 4.43 Million USD | -14.92% |
2009 Q4 | 4.43 Million USD | -9.85% |
2009 Q3 | 4.92 Million USD | -3.18% |
2008 Q1 | 5.93 Million USD | 0.51% |
2008 Q3 | 5.15 Million USD | -1.73% |
2008 Q4 | 5.21 Million USD | 1.15% |
2008 FY | 5.21 Million USD | -11.59% |
2008 Q2 | 5.24 Million USD | -11.51% |
2007 Q3 | 6.67 Million USD | -15.09% |
2007 Q4 | 5.9 Million USD | -11.57% |
2007 Q2 | 7.85 Million USD | 96.65% |
2007 Q1 | 3.99 Million USD | -0.47% |
2007 FY | 5.9 Million USD | 46.97% |
2006 Q4 | 4.01 Million USD | -7.94% |
2006 FY | 4.01 Million USD | -11.17% |
2006 Q1 | 4.46 Million USD | -1.25% |
2006 Q2 | 4.41 Million USD | -1.11% |
2006 Q3 | 4.36 Million USD | -1.19% |
2005 Q4 | 4.51 Million USD | -6.93% |
2005 Q3 | 4.85 Million USD | -0.69% |
2005 Q1 | 4.6 Million USD | 2.63% |
2005 Q2 | 4.88 Million USD | 6.09% |
2005 FY | 4.51 Million USD | 0.63% |
2004 Q2 | 3.63 Million USD | 0.0% |
2004 Q1 | 3.63 Million USD | -2.68% |
2004 FY | 4.49 Million USD | 20.4% |
2004 Q4 | 4.49 Million USD | 23.72% |
2004 Q3 | 3.63 Million USD | 0.0% |
2003 Q4 | 3.73 Million USD | 0.0% |
2003 Q2 | 3.74 Million USD | -0.65% |
2003 FY | 3.73 Million USD | -4.48% |
2003 Q1 | 3.77 Million USD | -3.42% |
2003 Q3 | 3.73 Million USD | -0.45% |
2002 Q4 | 3.9 Million USD | -0.97% |
2002 Q1 | 4.01 Million USD | -3.34% |
2002 Q2 | 3.98 Million USD | -0.92% |
2002 Q3 | 3.94 Million USD | -0.95% |
2002 FY | 3.9 Million USD | -6.06% |
2001 Q3 | 4.2 Million USD | -0.97% |
2001 FY | 4.15 Million USD | -5.94% |
2001 Q1 | 4.29 Million USD | -2.93% |
2001 Q2 | 4.24 Million USD | -1.05% |
2001 Q4 | 4.15 Million USD | -1.12% |
2000 Q3 | 4.46 Million USD | -1.48% |
2000 Q4 | 4.41 Million USD | -0.97% |
2000 FY | 4.41 Million USD | -1.39% |
2000 Q1 | 4.54 Million USD | 1.43% |
2000 Q2 | 4.53 Million USD | -0.35% |
1999 Q1 | 4 Million USD | -4.76% |
1999 Q2 | 4.2 Million USD | 5.0% |
1999 FY | 4.48 Million USD | 6.71% |
1999 Q4 | 4.48 Million USD | 12.04% |
1999 Q3 | 4 Million USD | -4.76% |
1998 FY | 4.2 Million USD | 1300.0% |
1998 Q1 | 4.3 Million USD | 1333.33% |
1998 Q2 | 4.4 Million USD | 2.33% |
1998 Q3 | 4.3 Million USD | -2.27% |
1998 Q4 | 4.2 Million USD | -2.33% |
1997 Q2 | 310 Thousand USD | 0.0% |
1997 Q3 | 3.3 Million USD | 964.52% |
1997 Q4 | 300 Thousand USD | -90.91% |
1997 FY | 300 Thousand USD | 50.0% |
1996 FY | 200 Thousand USD | 122.22% |
1995 FY | 90 Thousand USD | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 100.0% |
Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 100.0% |
SQZ Biotechnologies Company | 27.47 Million USD | 100.0% |
Evofem Biosciences, Inc. | 43.37 Million USD | 100.0% |
Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 100.0% |
Mesoblast Limited | 118.7 Million USD | 100.0% |
Propanc Biopharma, Inc. | 948.27 Thousand USD | 100.0% |
Genus plc | 233.1 Million USD | 100.0% |
VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 100.0% |
CNBX Pharmaceuticals Inc. | 1.34 Million USD | 100.0% |
Marizyme, Inc. | 18.71 Million USD | 100.0% |
ContraFect Corporation | 2.88 Million USD | 100.0% |
Nymox Pharmaceutical Corporation | 750 Thousand USD | 100.0% |
PsyBio Therapeutics Corp. | 135.48 Thousand USD | 100.0% |
Sienna Biopharmaceuticals, Inc. | - USD | NaN% |
RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | 100.0% |
Intellipharmaceutics International Inc. | 2.32 Million USD | 100.0% |
AXIM Biotechnologies, Inc. | 5.65 Million USD | 100.0% |
MultiCell Technologies, Inc. | 202.58 USD | 100.0% |
Accustem Sciences Inc. | - USD | NaN% |
RVL Pharmaceuticals plc | 57.48 Million USD | 100.0% |
EV Biologics, Inc. | 1.49 Million USD | 100.0% |
Q BioMed Inc. | 4.1 Million USD | 100.0% |
Emmaus Life Sciences, Inc. | 33.1 Million USD | 100.0% |
Neon Bloom, Inc. | 630.07 Thousand USD | 100.0% |
Mosaic ImmunoEngineering Inc. | 1.22 Million USD | 100.0% |
Biomind Labs Inc. | 735.54 Thousand USD | 100.0% |
TetraLogic Pharmaceuticals Corporation | - USD | NaN% |
Pharming Group N.V. | 171.54 Million USD | 100.0% |
Oncotelic Therapeutics, Inc. | 12.99 Million USD | 100.0% |
Skye Bioscience, Inc. | 4.61 Million USD | 100.0% |
Therapeutic Solutions International, Inc. | 888.06 Thousand USD | 100.0% |
THC Farmaceuticals, Inc. | 141.51 Thousand USD | 100.0% |
Arch Therapeutics, Inc. | 5.87 Million USD | 100.0% |
IMV Inc. | 28.88 Million USD | 100.0% |
Acro Biomedical Co., Ltd. | 25.71 Thousand USD | 100.0% |
Curative Biotechnology, Inc. | 2.25 Million USD | 100.0% |
GB Sciences, Inc. | 1.75 Million USD | 100.0% |
Alpha Cognition Inc. | 1.22 Million USD | 100.0% |
HST Global, Inc. | 98.31 Thousand USD | 100.0% |
CSL Limited | 12.18 Billion USD | 100.0% |
Halberd Corporation | 150 Thousand USD | 100.0% |
Enzolytics Inc. | 996.33 Thousand USD | 100.0% |
Resverlogix Corp. | 6.49 Million USD | 100.0% |
Affymax, Inc. | - USD | NaN% |
SYBLEU INC | 477.5 Thousand USD | 100.0% |
Nuo Therapeutics, Inc. | 255.59 Thousand USD | 100.0% |
argenx SE | 20 Million USD | 100.0% |
MetaStat, Inc. | - USD | NaN% |
Northwest Biotherapeutics, Inc. | 45.56 Million USD | 100.0% |
Enzon Pharmaceuticals, Inc. | - USD | NaN% |
Arno Therapeutics, Inc. | - USD | NaN% |
RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 100.0% |
GeneThera, Inc. | - USD | NaN% |
AVAX Technologies, Inc. | - USD | NaN% |
Zenith Capital Corp. | 10.22 Thousand USD | 100.0% |
Genscript Biotech Corporation | 417.73 Million USD | 100.0% |
Ember Therapeutics, Inc. | 200.61 Thousand USD | 100.0% |
Anthera Pharmaceuticals, Inc. | - USD | NaN% |
Sigyn Therapeutics, Inc. | 2.39 Million USD | 100.0% |
WPD Pharmaceuticals Inc. | 229.29 Thousand USD | 100.0% |
American Oriental Bioengineering, Inc. | 67.64 Million USD | 100.0% |
Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 100.0% |
Adynxx, Inc. | - USD | NaN% |
Helix BioMedix, Inc. | - USD | NaN% |
GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 100.0% |
VitaSpring Biomedical Co. Ltd. | - USD | NaN% |
Capstone Therapeutics Corp. | 20.32 Million USD | 100.0% |
Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | 100.0% |
BioStem Technologies, Inc. | 4.71 Million USD | 100.0% |
ONE Bio Corp. | 19.71 Million USD | 100.0% |
Reve Technologies, Inc. | 250.18 Thousand USD | 100.0% |
Burzynski Research Institute, Inc. | - USD | NaN% |
Wesana Health Holdings Inc. | 248.72 Thousand USD | 100.0% |
Agentix Corp. | 50 Thousand USD | 100.0% |
LadRx Corporation | 33.6 Thousand USD | 100.0% |
Cell Source, Inc. | 9.25 Million USD | 100.0% |
ProtoKinetix, Incorporated | - USD | NaN% |
Regen BioPharma, Inc. | 756.2 Thousand USD | 100.0% |
Regen BioPharma, Inc. | 756.2 Thousand USD | 100.0% |
NovAccess Global Inc. | 2.19 Million USD | 100.0% |
Endonovo Therapeutics, Inc. | 7.07 Million USD | 100.0% |
Itoco Inc. | 228.37 Thousand USD | 100.0% |
Rasna Therapeutics, Inc. | 210.97 Thousand USD | 100.0% |
Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 100.0% |
Kadimastem Ltd | 891.22 Thousand USD | 100.0% |
Oncology Pharma Inc. | - USD | NaN% |
Institute of Biomedical Research Corp. | 401.84 Thousand USD | 100.0% |
CytoDyn Inc. | 30.07 Million USD | 100.0% |
Claritas Pharmaceuticals, Inc. | - USD | NaN% |
NDT Pharmaceuticals Inc. | - USD | NaN% |
Mobile Lads Corp. | 484.28 Thousand USD | 100.0% |
NanoSphere Health Sciences Inc. | - USD | NaN% |
Qrons Inc. | 351.84 Thousand USD | 100.0% |
Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 100.0% |
Advanced Proteome Therapeutics Corporation | - USD | NaN% |
Nascent Biotech, Inc. | 122.5 Thousand USD | 100.0% |
Rebus Holdings, Inc. | 310 Thousand USD | 100.0% |
ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 100.0% |
International Stem Cell Corporation | 4.17 Million USD | 100.0% |
Bioxytran, Inc. | 1.92 Million USD | 100.0% |
GlobeImmune, Inc. | - USD | NaN% |
Predictive Technology Group, Inc. | - USD | NaN% |
ProText Mobility, Inc. | 62.41 Thousand USD | 100.0% |
Cardax, Inc. | - USD | NaN% |
VG Life Sciences Inc. | 2.18 Million USD | 100.0% |
Kaleido Biosciences, Inc. | - USD | NaN% |
Advaxis, Inc. | 8.31 Million USD | 100.0% |
Adhera Therapeutics, Inc. | 8.58 Million USD | 100.0% |
RenovaCare, Inc. | - USD | NaN% |
Regnum Corp. | 1.55 Million USD | 100.0% |
Innovation Pharmaceuticals Inc. | 268 Thousand USD | 100.0% |
Neutra Corp. | 54.15 Thousand USD | 100.0% |
Windtree Therapeutics, Inc. | 1.83 Million USD | 100.0% |
PureTech Health plc | 25.51 Million USD | 100.0% |
Coeptis Therapeutics, Inc. | 1.22 Million USD | 100.0% |
IXICO plc | 472.02 Thousand USD | 100.0% |
IntelGenx Technologies Corp. | 15.5 Million USD | 100.0% |
Gelesis Holdings, Inc. | 62.26 Million USD | 100.0% |
CSL Limited | 12.18 Billion USD | 100.0% |
Cellectis S.A. | 92.77 Million USD | 100.0% |